| Names | |
|---|---|
| Preferred IUPAC name | 2,6-diaminohexanoic acid |
| Other names | L-Lysine Diaminohexanoic acid L-2,6-Diaminocaproic acid |
| Pronunciation | /diː-ɛl-ˈlaɪsiːn/ |
| Identifiers | |
| CAS Number | 922-51-0 |
| Beilstein Reference | 2605763 |
| ChEBI | CHEBI:59826 |
| ChEMBL | CHEMBL1377 |
| ChemSpider | 84699 |
| DrugBank | DB00144 |
| ECHA InfoCard | 04c1e92f-9173-4b82-a26c-2780d7d512f1 |
| EC Number | 3.2.1.37 |
| Gmelin Reference | 5893 |
| KEGG | C00189 |
| MeSH | D08BT02 |
| PubChem CID | 61577 |
| RTECS number | OA5950000 |
| UNII | J0HK02F792 |
| UN number | 2811 |
| CompTox Dashboard (EPA) | DL-Lysine: "DTXSID3035783 |
| Properties | |
| Chemical formula | C6H14N2O2 |
| Molar mass | 146.19 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.1 g/cm3 |
| Solubility in water | Soluble in water |
| log P | -3.0 |
| Acidity (pKa) | pKa 2.18 (carboxyl), 8.95 (amino), 10.53 (side chain) |
| Basicity (pKb) | pKb: 4.21 |
| Refractive index (nD) | 1.521 |
| Dipole moment | 6.56 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 259.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -182.79 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3763 kJ/mol |
| Pharmacology | |
| ATC code | A16AA21 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, Warning, H315, H319, H335, P261, P305+P351+P338 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | Not a hazardous substance or mixture. |
| Precautionary statements | Wash thoroughly after handling. Do not eat, drink or smoke when using this product. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Autoignition temperature | 393°C (739°F) |
| Lethal dose or concentration | LD50 (oral, rat): > 5,000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral 5 g/kg |
| NIOSH | Not established |
| PEL (Permissible) | 15 mg/m³ |
| REL (Recommended) | 3.0% |
| IDLH (Immediate danger) | No IDLH established |
| Related compounds | |
| Related compounds | L-Lysine D-Lysine Epsilon-Caprolactam Aminocaproic acid |
| Product Identification | |
|---|---|
| Product Name | DL-Lysine |
| IUPAC Name | 2,6-diaminohexanoic acid |
| Chemical Formula | C6H14N2O2 |
| Synonyms & Trade Names | α,ε-Diaminohexanoic acid, racemic Lysine |
| HS Code & Customs Classification | 2922.41 (Amino acids, their esters; salts thereof, specifically for Lysine and its esters) |
Manufacturing teams regularly verify the correct assignment of CAS number and nomenclature during raw material registration and prior to product release. The structural formula C6H14N2O2 reflects both the production route and final crystal form sourced from either synthetic racemization or non-chiral precursors.
In process review meetings, the team differentiates between DL-, L-, and D- forms. DL-Lysine appears as a racemic mixture, which impacts optical activity testing and product labelling obligations under regional market regulations. During customs documentation, the correct HS code (2922.41) ensures streamlined export clearance and accurate declaration of content, as different derivatives and purity grades can attract varying duties.
The technical grade, pharmaceutical grade, and feed-grade variants receive unique internal codes. Physical properties, including solubility and crystallinity, can shift with grade-specific process adjustments. Industrially, the DL- form does not meet nutritional application standards, so export is more often aimed at chemical synthesis and intermediate use rather than direct use in food or feed.
The presence of both enantiomers in DL-Lysine requires careful documentation on batch records, especially for integration into catalytic routes or chiral separation stages. Any ambiguity in labeling or customs declaration can cause delays or compliance risks at the border, so quality assurance teams inspect every export batch for agreement with specifications filed to border authorities and customers.
DL-Lysine produced in bulk typically forms a white to off-white crystalline or powdery solid. Color intensity and form relate to process route, grade, and impurity removal efficiency. Crystalline forms appear more common in higher purity pharmaceutical or food grade, whereas technical grade may contain slight tint or agglomerates from handling and storage. Odor remains faint and characteristic due to the amino acid backbone, but off-odors can suggest impurity carryover or storage at excessive temperature and humidity. Melting point ranges may show minor batch-to-batch variation, reflecting both optical isomer composition and residual solvent traces; extreme control in chiral purity can further tighten the melting range for specialized applications. Boiling and flash points do not directly pertain due to the decomposition profile at elevated temperatures.
Chemical stability for DL-Lysine hinges on moisture protection and temperature. Exposure to ambient humidity accelerates deliquescence and risks Maillard browning if in contact with reducing sugars, especially during extended storage or in mixed formulations. The alpha-amino group remains chemically accessible, which can lead to racemization or degradation under strong acid/base conditions or high heat. Batch stability is generally supported by inert gas blanketing for sensitive grades and strict lot segregation to avoid cross-contamination.
Solubility in water stands high, but the actual dissolution rate varies with grade, particle size, and residual moisture content. Process-side granulation and milling impact wetting behavior—fine powders dissolve readily but risk lump formation in high humidity. Aqueous solution preparation for blending, fermentation, or feed premix typically requires staged addition with agitation. Organic solvent compatibility stays low, except in specialized downstream modification conditions.
Specification ranges respond to end-use requirements. Food and feed grades target residual impurity and microbial contamination limits set by corresponding regulations, while pharmaceutical grades enforce stricter optical purity, heavy metal, and endotoxin control. Each grade is supplied with a COA declaring actual test points.
Impurity sources include incomplete conversion, racemization, catalyst residues, and process-side byproducts. Limits for specific inorganic ions, color bodies, unreacted raw materials, or organic solvents are tightly managed for injectable or food grade. Technical grade tolerates marginally wider impurity limits if the downstream user’s process allows it. Each profile reflects both process capability and target sector compliance.
Manufacturers primarily apply titrimetric assays, HPLC with chiral detection, and mass balance. Method validation aligns with global pharmacopeia or feed compendium for corresponding grades. Instrument calibration and sample handling protocols ensure consistency, reinforced by periodic proficiency testing of QC staff and cross-checking with reference standards.
Manufacture typically employs petrochemical or fermentation-derived precursors. Raw material selection prioritizes not just purity, but traceability, GMO status (for fermentation), and supply chain stability. Each procurement cycle involves supplier audit and periodic raw material requalification.
For DL-Lysine, racemic synthesis by chemical condensation often proceeds using precursors such as caprolactam or alpha-keto acids under catalytic hydrogenation. Manufacturers align route selection to feedstock price volatility, desired enantiomeric excess, and regulatory compliance for food/pharma grades. Side-reactions and byproduct formation are mapped in pilot studies and reviewed if process chemistry is adjusted.
Control points start with raw material acceptance then focus on reaction conditions (pH, temperature, catalyst activity, agitation rate), followed by phase separation, crystallization, and multi-step washing or filtration. Purification protocols differ by grade: food/pharma grades require solvent removal validation, heavy metal clearance, and microbial control throughout final drying and packaging. Heavier technical grades often employ simplified purification, delivering higher throughput where application tolerates minor impurities.
Quality control incorporates in-process monitoring for reaction completion, batch homogeneity, and impurity rejection. Release standards depend on grade and end market, guided by both regulatory submissions and customer qualification. Final product undergoes identity, purity, and physicochemical assessment before release. Batch records maintain traceability and document interventions in case of process deviations.
The molecule’s amino and carboxyl groups allow for amidation, acylation, esterification, and peptide bond formation. Common reactions for value-add include conversion to various lysine salts or coupling into protected intermediates for peptide synthesis.
Modification may employ acid, base, or enzymatic catalysis; temperature and solvent choice adapt to required selectivity and downstream application. Technical teams select catalysts and solvents tailored to batch size and impurity sensitivity. Use in pharmaceutical routes relies on low-residual catalyst systems.
Downstream processes utilize DL-Lysine as a precursor for specialty chemicals, flavor modifiers, or as a building block in complex molecule development. Desired derivative purity and stability shape upstream process cleanliness, since residual unreacted lysine or byproducts impact yield and product performance.
Long-term stability depends on temperature control, low humidity, and avoidance of direct light. Ambient temperature is practical for technical and feed grades, whereas low temperature storage dominates pharmaceutical specifications to limit racemization and degradation. Product shows hygroscopicity, so air-tight sealed containers often include desiccant packs, and warehouse monitoring logs track both temp and RH excursions.
Packaging involves high-density polyethylene or lined fiber drums. Compatibility with both chemical and physical properties of the product stays critical to prevent sorption or migration—assurance steps include periodic leachability testing, especially for pharmaceutical supply.
Shelf life depends on grade, packaging integrity, and storage discipline. Typical signs of degradation include discoloration, odor shift, and caking from moisture ingress. Retain samples undergo periodic testing for specification compliance at prescribed intervals, depending on batch audit strategy.
Hazard classification depends on purity and physical form but generally reflects low acute toxicity for industrial grades. Specific details for hazard codes and pictograms conform to regional requirements; full documentation accompanies each shipment.
Handling guidance stresses avoidance of dust formation and inhalation, use of standard lab PPE, and attention to possible skin or eye irritation from prolonged contact. Manufacturer guidance updates based on regulatory revisions or incident reports from downstream users.
Toxicological profile demonstrates low oral and dermal toxicity at workplace exposure levels. Specific limits for chronic exposure, reproductive toxicity, or environmental impact align with published data and undergo internal review if new studies become available.
Exposure limits and safe handling depend on regional regulatory standards and intended use sector. Production and packaging lines employ LEV and enclosed transfer systems to minimize airborne dust. Incident response training includes spill containment, first-aid, and decontamination procedures, tailored for grade and end-use markets.
Geographically, industrial DL-Lysine production centers around integrated fermentation and synthetic plants, typically co-located with feed and food-grade amino acid complexes. Capacity hinges on raw material allocation, fermenter turnaround, and purification throughput. Months with optimal sugar feedstock and stable utilities tend to push output up, but batch interruptions from fermentation pressure drops or bioburden can tighten short-term supply. For technical and standard feed grades, output fluctuates per client scheduling and targeted inventory levels.
Standard industrial lead times for domestic shipments range from two to four weeks from order confirmation, reflecting batch campaign scheduling and downstream QA turnaround. Export orders, especially for custom grade or certification, may require additional two to three weeks for documentation and ocean container bookings. Typical minimum order volume is defined per grade—bulk feed or technical grades generally start at one full pallet, custom-packaged or high-purity grades require plant-side consultation depending on process slotting and demand pooling.
Bulk and semi-bulk formats—20-25kg fiber drums, 500kg to 1000kg super bags—comprise the majority of outbound volume. Higher purity and food/pharma grades may go into sealed PE inner bags with exterior drums or boxes, contingent on end-use contamination sensitivity and regional transit requirements. Custom packaging, such as foil-lining or nitrogen flushing, can be negotiated for sensitive or export contracts, provided process line changeover time aligns with production scheduling.
EXW, FOB, and CIF terms dominate export transactions, with payment instruments negotiated based on counterparty risk (LC or advanced TT) and country. Domestic contracts frequently settle on net 30-day terms to pre-qualified processors. In-plant loading is coordinated to minimize demurrage and keep DL-Lysine within specified transit and humidity limits, a key consideration for less stable, high-hygroscopicity specialty grades.
Corn or sugar feedstock cost carries the greatest influence in total cost structure, compounded by fermentation nutrient input, energy, and catalysis efficiency for DL-Lysine route selection. Fluctuations primarily track with grain market shifts—droughts, trade policy, or biofuel demand can push fermentable feedstocks higher, which immediately strains cost projections and contracts. Enzyme or catalytic inputs, usually regionally sourced, introduce secondary volatility, particularly when process route switching occurs to offset upstream issues (e.g., bacterial contamination or sugar impurity spikes).
Price banding follows grade—feed/tech, food, then pharma—with increments explained by tighter impurity limits, validated batch records, and additional certification overhead (ISO, FAMI-QS, Halal, Kosher, etc.). Packaging also contributes—a fiber-drum export with nitrogen flush commands a premium over standard woven sack. Country-specific approval and analytical testing, critical for export to US/EU/JP, add to the per-metric ton price where such documentation is required.
Demand tracks tightly with monogastric animal feed and, to a lesser extent, direct food fortification. North America, Europe, and China anchor the consumption base, but India's capacity expansion and regulatory liberalization make it an emerging element. Japan's preference for high-traceability food/pharma grades sets a clear differentiation in specification and price. Periods of Chinese anti-dumping investigations or supply curbs coincide with temporary price lifts across Asia and into trans-Atlantic markets.
US/EU commit to premium-priced, high-purity or specialty blends, with regulatory and sustainability claims front and center. China maintains scale leadership; competitive local pricing comes at the cost of batch-to-batch grade variability and periodic logistics snarls. India leans on imports but domestic policy shifts opening FDI in feed manufacturing could alter the landscape by 2026. Japan builds supply around long-term quality contracts from validated sites only, with high documentation overhead.
Expectation centers on gradual upward price pressure through 2026, conditional on grain and energy markets, as well as environmental control costs imposed on fermentation sectors (most acutely in China and the EU). Regulatory tightening for cross-border shipments and new certification mandates could further push premiums on specialty grades. Forecasts use a weighted blend of raw material spot market movements, utility futures, published customs data, and historical plant operation cycles.
Consolidation in upstream fermentation tech has improved batch output in Asia, though ongoing raw sugar volatility and water restrictions introduce uncertainty for long-term contract planning. European market responded to new feed additive limits on biogenic amines with incremental demand for higher-purity batches.
Recent shifts in EU traceability law and maximum residue thresholds, along with ongoing updates to China’s export permit requirements, mandate recalibration of export documentation and in-process compliance checks. US FDA and Japanese MHLW have introduced audit protocols focusing on allergen controls and process water validation in final release.
Internal strategy prioritizes redundancy in feedstock sources, cross-qualification of alternative fermentation nutrients, and on-demand process tweaking to meet region-specific impurity and documentation mandates. Increased investment in in-line monitoring and micro-contaminant mitigation forms the backbone of batch consistency and release timing, especially as customer audits and regulatory inspections increase in frequency.
DL-Lysine from our plant reaches sectors with distinctly different technical baselines. Our routine batches typically target animal feed, food ingredient, nutritional fortification, and pharmaceutical synthesis. In animal feed, lysine acts as a balancing essential amino acid, supporting growth and protein utilization. Food fortification demands stringent purity with tight contaminant control, where product origin and processing steps feature in risk assessment. Pharmaceutical applications push requirements further, including extended analytical verification for isomer ratio, contaminant residues, and trace solvents, all documented for regulatory submission. Bulk chemical synthesis, including peptide and intermediate production, relies on predictable reactivity and physical handling (such as hygroscopicity and bulk density).
| Application Sector | Typical Grade(s) | Key Technical Drivers | Process Attention |
|---|---|---|---|
| Animal Nutrition | Feed Grade | Amino acid content, flowability, residual solvent profile | Batch particle size uniformity, dust minimization, by-product trace control |
| Food & Beverage | Food Grade | Heavy metal residuals, microbial load, allergens | Dedicated line segregation, food-contact equipment qualification |
| Pharmaceuticals | Pharma Grade | Stereoisomeric purity, elemental impurity screening, trace solvents | Polymer-grade filtration, validated cleaning, GMP-compliant release |
| Chemical Synthesis | Technical Grade / Custom Purified | Processability, by-product residuals, moisture content | Process route disclosure, blending controls |
Feed grade prioritizes total lysine assay and dust control. In food applications, color, odor, microbial profile, and heavy metals receive priority, often with separate storage and batch coding. Pharma grade compels batch-to-batch stereopurity verification, pyrogen-free status, and validated impurity removal. Technical grade often focuses on ease of dissolution and batch consistency rather than regulatory-tested purity.
The primary use—be it nutrition, synthesis, or specialty formulation—determines the suitable product grade. Animal nutrition or bulk synthesis usually tolerates wider specification windows, while food and pharmaceutical customers demand strict certification trails.
Align the grade with prevailing standards. Food and pharma grades often require compliance checks against local regulations, such as food additive codes or pharmacopeia monographs. Process documentation, identification of critical control points, and relevant certification reports should be reviewed at this stage.
Assess what level of lysine purity, isomer profile, and contaminant exclusion is technically necessary. Pharmaceutical formulas and injectable uses need strict limits on trace impurities, while feed or synthesis sectors often value assay and physical compatibility.
Production economics influence grade feasibility. Higher purity, enhanced traceability, or narrower batch release intervals usually bring cost implications. Calculate batch sizes and long-term supply needs, as large volumes could justify custom process modifications.
Before committing to full-scale procurement, request product samples for test runs. A sample lot enables real-world compatibility checks, including dissolution trials, stability assessments, and downline analytics. Adjustments to grade release, packaging, or carrier system can be implemented after technical validation.
Raw material qualification starts at the supplier audit—traceability and precise isomer content are logged. Process route selection usually balances throughput, impurity breakdown, and isomer control; for food and pharma, proprietary purification steps split DL- and L-isomers and minimize heavy metals, solvent traces, and volatile by-products. Critical quality points focus on solution filtration, drying controls (to avoid degradation), and blending for bulk physical consistency.
Batch consistency comes from inline process analytics and periodic full-lot testing. Release criteria depend on grade: animal feed allows for wider ranges in physical characteristics; food and pharma undergo detailed residual and isomeric analysis, with hold-and-release steps enforced until all safety testing clears.
Our technical support remains available for application-specific tailoring—process modifications, impurity profiles, and analytical method transfers form the core of our customer adaptation work.
Quality management systems form the backbone of every batch release. Our DL-Lysine facilities operate under full quality management certification according to ISO standards. For each production site, we maintain detailed records of audit outcomes, traceability logs, and process corrections. We implement layered in-process control steps tailored to the criticality of each stage, such as fermentation, purification, and drying. The most relevant certifications are site-specific and periodically updated according to current compliance schedules. Audit documentation and maintenance logs are available for all manufacturing campaigns on request, supporting supplier qualification efforts and any regulatory due diligence by customers.
Certifications for DL-Lysine derive from both the input raw materials and compliance with downstream applications, such as feed, food, or pharmaceutical usage. Production lines dedicated to food or pharma grades apply additional hygiene, allergen control, and contaminant risk mitigation beyond basic GMP requirements. Certificates of analysis accompany every shipment and display test outcomes against defined grade-dependent criteria. Halal, Kosher, and non-GMO attestations are possible, depending on feedstock and process route, and are not universally applicable across all grades or plants. Customers requiring specific certifications should initiate requests during early technical discussions, as lead times depend on audit cycles and third-party certifier schedules.
Batch documentation for DL-Lysine includes full lot traceability, release test reports, and in-process monitoring records. Standard documentation entails certificates of analysis, statements on residual solvents, allergens, and microbial load where relevant, and process deviation reports if applicable. Phytosanitary or veterinary certificates for feed-grade materials are prepared per shipment, dependent on export region requirements. For food and pharma grades, auditors receive unredacted versions of change control and deviation management logs as part of qualification audits. Redacted summaries are available for non-disclosure-sensitive enquiries.
Our production lines run on dedicated fermentation and recovery platforms, with capacity planning anchored in multi-year tracks for primary customers. Production scheduling algorithms allocate available capacity by segmenting campaign runs according to grade, customer, and seasonal demand. Flexibility in supply commitments relies on dynamic adjustment to fermenter turnarounds and buffer storage. Our business terms may incorporate contract manufacturing, forward purchase agreements, and ad hoc dispatch for small-volume or application trial requests. Volume ramp-up or reduction can be negotiated as part of annual framework agreements.
The core of our output depends on vertical integration of key fermentation nutrients, on-site utilities, and centralized purification clusters. Maintaining uninterrupted DL-Lysine supply requires redundancy in reactor and dryer stages, as well as multi-source approval for all critical process materials. Proactive management of supply risk includes advance raw material procurement, predictive maintenance of reactors, and overcapacity buffers for market-driven upswings. Supply assurance targets high-priority segments by volume and end-use criticality.
Sample requests for DL-Lysine move through a controlled chain of internal review for grade suitability, quantity, and compliance with customer use case. Applications are screened by technical support staff who assess application fit—feed, food, or technical grade—before allocation from current QA-released inventory. Documentation accompanying samples mirrors the main commercial batch package, including testing reports specific to the customer’s intended application. Formal non-disclosure or technical evaluation agreements may be required before dispatch for proprietary or specialty applications.
Direct partnership can take several forms: spot purchase, rolling order programs, term supply contracts, and consignment stock arrangements. High-volume customers may opt for dedicated campaign runs, with joint scheduling managed between our logistics and the customer’s procurement team. For innovation or development projects, we support milestone-based supply, linking each stage delivery to application feedback and technical optimization loops. Custom documentation, packaging, and even traceable labeling are part of these flexible models, subject to agreement and internal technical feasibility reviews.
In DL-Lysine manufacturing, current research centers on optimizing fermentation efficiency, exploring feedstock flexibility, and improving product purity across different production scales. Work focuses on enhancing microbial strains to increase output and reduce byproduct load. Process teams prioritize raw material selection for cost and availability while minimizing impurities such as residual sugars and amines. Control points include pH regulation, temperature management, aeration rates, and nutrient balance, all of which display a direct impact on batch yield and overall cost structure.
End-users in food fortification, animal nutrition, and certain specialty chemical sectors are driving new demand profiles for DL-Lysine. Applications now extend into niche formulations for aqua feed, fermentation media, and biodegradable polymer synthesis. Several customers demand specific grades based on solubility, particle size, and residual moisture. Industrial users with customized specifications require tight control on optical purity and co-product content, with some grades tailored for downstream modification.
Key challenges include managing byproduct removal, maintaining product stability through various storage and transport conditions, and minimizing energetic inputs per unit output. Recent breakthroughs in bioreactor design and in-line analytics have shortened process cycles and improved batch consistency. In-process monitoring with advanced sensors allows for proactive impurity control. Purification step improvements, particularly in crystallization and centrifugation, have reduced waste and lowered energy intensity. Breakthroughs in recycling process water have further minimized operational footprints.
Projected demand for DL-Lysine shows an upward trend, driven by tightening protein sourcing requirements in feed and food sectors. Supply constraints in primary raw materials, such as carbohydrates and specific nitrogen sources, influence cost structures. Market segmentation increasingly depends on application sensitivity to purity and process origin. Pricing dynamics reflect regional feedstock prices and regulatory influences on amino acid supplementation.
Fermentation technology will shift toward continuous processing and modular reactor systems. Adoption of synthetic biology in strain engineering aims to elevate yields on non-traditional substrates. Upgrades in digital control for real-time quality assurance reduce deviation and batch-to-batch variation. Manufacturing teams regularly re-evaluate their process route, selecting between classical fermentation, enzymatic conversion, or hybrid chemistry, depending on raw material logistics, sustainability targets, and local infrastructure.
Manufacturers are integrating life cycle assessments into raw material sourcing and waste management design. Process water recapture, biochemical oxygen demand reduction, and the use of renewables in operations represent core sustainability investments. Green chemistry principles are applied through reduction of hazardous reagents, improvement in atom economy, and recovery of side-streams for valorization. Each process upgrade must demonstrate a tangible reduction in environmental impact before scale-up decisions receive approval.
Process engineers and quality control specialists provide application-specific guidance on grade selection, product compatibility, and formulation optimization. Each recommendation draws from in-process data, production records, and observed application outcomes under actual field conditions. Troubleshooting covers issues such as solubility at various pH, compatibility with co-formulants, and adjustment of use rates based on regional dietary regulations. Solutions remain tailored to the customer’s equipment, product flow, and regulatory environment.
Technical teams collaborate in downstream process validation to enhance yield and minimize wastage during blending and packaging. Support includes assistance with scale-up, batch-to-batch reproducibility, and impurity profile management. Customers in sensitive dosage applications receive recommendations for storage conditions, and for minimizing cross-contamination risk throughout the value chain. Optimization focus extends to moisture control, dissolution rate, and bulk density, which are adjusted as required by customer process feedback.
Commitment to consistency and quality stretches beyond product release. Each batch receives traceability documentation and quality verification aligned to customer-specific benchmarks. Complaint management routes directly to production and quality teams, who review QA archives and re-test retention samples if anomalies occur. Technical staff authenticate the origin and compliance of each shipment, issuing corrective and preventive actions where needed and revising internal control plans where root cause analysis supports adjustment.
| Support Type | Core Offering | Industrial Relevance |
|---|---|---|
| Consultation | Guidance on optimal grade, process troubleshooting, in-plant audits | Ensures correct integration into complex production lines with feedback loops to manufacturing |
| Optimization Support | Formulation tuning, scale-up assistance, impurity and stability troubleshooting | Reduces incidence of off-spec batches and addresses downstream reliability issues |
| After-Sales Service | Batch traceability, rapid incident response, corrective action verification | Drives long-term customer confidence and supports regulated industries’ audit requirements |
DL-Lysine takes a core position in several industrial sectors that value both consistency in supply and strict control over product specifications. As the manufacturer responsible for every stage of production, we support global industries seeking secure supply and precise product attributes. The entire process is rooted in large-scale fermentation and separation technology, where we maintain direct oversight—from feedstock input through to the final packaging line.
We produce DL-Lysine for buyers operating in diverse segments such as feed formulation, pharmaceuticals, and chemical synthesis. Major feed integrators rely on the regular delivery and nutritionally specified content, as poultry and aquaculture facilities operate on fine tolerances for amino acid blends. Pharmaceutical and specialty chemical companies leverage the enantiomeric balance and high purity to underpin their synthesis routes, where consistency and trace profile impurities matter to performance and regulatory review. In these markets, predictable product performance comes directly from the controlled parameters we set at the manufacturing level.
Quality assurance begins on the plant floor, not with finished product checks, but with real-time monitoring of process variables and in-plant analytical systems. Batch records for DL-Lysine cover all operational aspects, with in-process control points managing critical purity data, moisture, particle size, and microbial metrics. Final lots see additional laboratory validation—every outgoing shipment matches our registered specification profile, which is traceable by lot from raw material to packaged goods. This traceability stands behind each shipment and provides manufacturers with predictable results, supporting downstream quality audits and compliance checks.
Packaging operations follow a modular system that accommodates the requirements of bulk users and contract pack formats. High-throughput bagging lines provide industrial sacks for integrators and larger pharma plants, while smaller, sealed units supply batch-level material for specialty use and pre-mix operations. Warehousing and dispatch teams work in tandem with production planners, aligning output with firm customer forecasts. As a direct manufacturer, we handle every part of the loading and dispatch process, offering shipping documentation and certificate packages tailored to international end-use and regulatory need.
Our technical team draws from daily operational experience with DL-Lysine processes. Support for industrial customers extends well past shipment, with in-house technical engineers and chemists guiding process adaptation, formulation reviews, and change control. Troubleshooting is built upon firsthand experience in both plant operations and application development, ensuring that process changes or new product development initiatives receive practical, real-world input. Whether the requirement involves adjusting blending rates, compatibility checks, or introduction into new end-use streams, support is only offered based on data generated in our own labs and production runs.
Manufacturers, distributors, and procurement teams gain operational confidence and secure long-term supply through direct relationships with production. Material scheduling and contract manufacturing options support continuous operations, bridging demand peaks and process shifts with minimal risk of disruption. Inventory is actively managed at origin, supporting both just-in-time delivery models and forward-bulk ordering without resorting to third-party interventions or unknown supply links. Buyers receive the full commercial value of working with a chemical manufacturing plant—real control over specifications, reliable timelines, and technical dialogue that supports both short-term production cycles and long-term business planning.
In our production facilities, purity is a topic that sparks a lot of conversation, from raw material intake right through to the filling line. Our DL-Lysine batches consistently reach a purity level exceeding 98% on a dry basis, measured against recognized chemical standards. We keep tight control over process parameters, and our own laboratory tracks analytical results for every lot released. Meeting high purity standards is not just a regulatory checkbox, but a core commitment—a result of continuous investment in refining our synthesis, crystallization, and filtration steps. Any fluctuation in raw materials, reaction time, or even ambient humidity can nudge figures down, so both engineering and quality control constantly monitor upstream and downstream checks.
Most discussion about purity leads straight to the question: what analytical method is used? For DL-Lysine, our team applies acid-base titration, which remains a gold standard in the field. The procedure starts with accurate sample weighing, progressing through careful neutralization against a standardized acid solution. Our process chemists then track the endpoint using potentiometric methods, which cut out guesswork from color indicators and provide repeatable results. If a client’s downstream process relies on a more specific profile—like testing only the L-isomer fraction—we will also apply chiral chromatography, using high-performance liquid chromatography (HPLC) calibrated for amino acids. HPLC adds another layer of verification, especially for customers working in advanced pharmaceutical or nutritional blends.
Numbers alone rarely tell the full story behind an assay sheet. Our quality team documents trace impurities and keeps full records for organic and inorganic byproducts, all the way down to the low ppm level where required. If extraneous peaks show up in chromatography runs, we don’t just log them—we identify the root cause, whether it’s from synthetic intermediates, filtration residues, or packing materials. Routine cross-checks help our engineers tune batch parameters, so each drum from our loading dock matches the integrity our customers expect. Experience shows that major downstream process issues are often rooted in overlooked minor impurities, so our lab doesn’t rely on a single snapshot result.
We pay attention to changes in specification requests from end-users across nutrition, feed, and specialized industrial applications. Some request certificates that highlight trace metal content, others need low water content or a precise enantiomeric ratio. Our R&D team is equipped for both trial-sized and industrial-scale batch analysis, so we can run additional tests, such as elemental analysis by ICP or advanced photometric methods, when a custom spec is needed for regulatory or process reasons. Detailed assay and batch records are available on request, accompanied by full COA documentation to back up any figure we report. In markets where regulatory needs shift or clients pilot new applications, we’re prepared to adapt and support with the right analytical tool.
As the actual manufacturer, our reputation attaches directly to the way we validate our DL-Lysine—purity is not just about today’s specification but also tomorrow’s trust. Every assay and every product label reflect the outcome of hands-on work by our team. For customers looking for peace of mind in ingredient supply, our approach—rooted in real manufacturing experience and robust control—remains our strongest guarantee.
In bulk amino acid supply, details about packaging and delivery often set the tone for how production flows further downstream. Our manufacturing team has shaped our packaging and shipment processes around the steady demand for DL-Lysine, paying attention to ease of handling, loading density, and protecting the active ingredient against both moisture and cross-contamination.
Plant operators, formulators, and process engineers need packaging that fits their equipment and workflow. For most sectors – whether food enrichment, fermentation, pharma, or feed – handling efficiency makes a real difference to overall costs and safety. Our DL-Lysine leaves the packing line in multi-ply kraft bags with PE liners, typically filled to 25 kg net. Drums are a practical alternative for those with specific site logistics, usually filled to 50 kg or 100 kg, sealed to block air and environmental contaminants.
Some customers order true bulk – one metric ton in FIBCs (so-called “big bags”) designed to sit cleanly in container loads and on automated handling lines. FIBCs suit high-throughput plants using pneumatic transfer or direct discharge hoppers. We have refined our FIBC filling process over years, monitoring powder flow, moisture, and bag integrity to minimize loss during transport.
Suitability isn’t just about physical size. Weight and packaging type influence storage safety, dust control, and shelf life. Our technical team tests each batch for water activity, making sure it fits both domestic and international climate requirements. If a customer’s plant uses unique bag sizes or pallet configurations, our packing shop can prepare custom orders following a technical review.
Bulk amino acid orders involve more than pushing a button. Our product is synthesized, dried, milled, and sieved all in-house, allowing tight control and traceability. Standard items – the 25 kg bags and FIBCs in high-turnover configurations – usually ship within two to three weeks from confirmed order and payment. That timeline reflects our raw material inventory and regular production runs. When high demand pushes capacity, early scheduling with our sales office secures shipment slots.
If a customer requests unusual packaging or strict batch delivery (such as for pharma validation), our order desk factors in time for extra QA checks and possible packaging material sourcing. This can add a week or more. We always communicate forecasted shipment dates based on current output rather than market guesswork.
Shipping large volumes often requires export documentation, compliance reports, and container bookings. Our logistics team works directly on these steps so the product leaves our factory on a confirmed date. Customers using just-in-time inventory cycles know that reliable, consistent lead times maximize plant efficiency and keep lines running.
Customers count on predictable delivery and straightforward answers about DL-Lysine handling. We publish actual lead times and packaging options rather than generic claims. Our plant staff and QA chemists can answer technical questions about packaging compatibility, storage conditions, and features like anti-caking agents.
Our experience has shown that specifying packaging early during the order process, and locking in forecasted shipment windows, leads to fewer delays and transport issues. For those who need even faster turnarounds, we sometimes set aside buffer stock, but these allocations require advance agreement. By keeping all steps of manufacturing and packing in-house, we respond to special requests with direct action – not third-party promises.
European import controls carry strict requirements. The Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation shapes expectations for any manufacturer shipping DL-Lysine to Europe. Our technical and regulatory teams are fluent in these obligations. DL-Lysine production follows internal protocols anchored in these frameworks right from raw material sourcing to batch release.
Every REACH registration calls for substance identification, safety data, and information regarding exposure potential throughout the supply chain. We maintain full annual registration for our DL-Lysine, with dossier submissions updated according to ECHA feedback and legislative changes. All supporting analytical data and toxicological results stem from verified laboratory methods and are available for customer review. Traceability is direct: from tracked raw material inputs through manufacturing environment, each lot enters the global market with documentation matching REACH and other international standards such as US TSCA, China MEE, or Japan CSCL.
Trade flows do not pause with Europe. In the Americas and Asia, authorities expect documentation on contaminant controls, heavy metal profiles, and allergen status. Our production facilities in China operate under certified quality management and environmental protocols. All process waste streams meet both local and export-destination standards before shipment. Audit teams carry out annual on-site inspections—internal and external—to ensure continued adherence to both host country and destination country requirements.
We recognize the challenge regulators face with imports that skirt transparency. Regulatory frameworks do not always align across borders; the best way forward means exceeding the most stringent customer-destination requirements. Our documentation for exported DL-Lysine, including extended Safety Data Sheets and analytical test reports, frequently goes beyond the minimum. For example, for European shipments, our SDS format delivers section-by-section compliance, hazard classification per CLP, and transport compatibility under ADR, IMDG, and IATA codes. Consignment paperwork, including labeling and packaging, is updated with every amendment in GHS regulations or country directives.
Risk management depends on solid information. Our in-house compliance and legal team reviews control parameters for each export country, submits new notifications as regulatory databases update, and maintains certificates needed by customs authorities or health ministries. We keep our customers informed about evolving regulatory trends, recalling cases in recent years where REACH requirements shifted and full dossier revisions became necessary for continued market access.
Border holds or shipment delays often trace back to missing documentation or ambiguous identification. To circumvent these issues, export procedures always include original signed REACH registration confirmation and, if requested, attestations on compliance with import-specific rules such as food or feed grade restrictions. Where authorities request local notifications, our local agents provide required import-of-record services and coordinate with customs directly.
Any modification in synthesis route or raw material selection passes through a regulatory change-control process. With each process adjustment, we update substance identity records, re-submit physical-chemical and toxicological data as needed, and inform customers if these changes affect certifications.
Our commitment remains ongoing: regulatory compliance for DL-Lysine rests on technical knowledge, detailed recordkeeping, and open communication both with oversight agencies and partners abroad. We stand behind every shipment and are prepared to address future regulatory questions as new rules and standards emerge on the global scene.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
